dddd
PublishedNovember 25, 2020

Changes Reducing IPR Institution Rate Have Increased Litigation Frequency and Cost

The U.S. Patent and Trademark Office’s precedential opinions on discretionary denial are the subject of significant attention—a withdrawn attempt by the Trump Administration to codify discretionary denial as a rule, a request for comments on rulemaking by the Office, and a challenge to the practice of discretionary denial as illegal under the Administrative Procedure Act.

The attention is deserved.  Fundamentally, discretionary denial has harmed the patent ecosystem, reversing the positive changes observed in patent litigation frequency and cost.  The changes even appear to have increased the cost of IPR itself.  Using cost data from AIPLA’s Report of the Economic Survey, decision analysis from Unified Patents, and statistical data from the PTO itself, the following charts show a clear correlation of the implementation of discretionary denial and these negative impacts on the patent system.

PTO’s Discretionary Denial Changes

The primary drivers of the discretionary denial changes are the General Plastic (Oct. 2017), Valve I (May 2019) and Valve II (Aug. 2019), NHK Spring (May 2019), and Fintiv (May 2020) precedential decisions.  

General Plastic created a set of non-statutory factors to be applied to determine if a prior petition by the same party justified denial of institution.  Valve I and Valve II expanded this inquiry to prior petitions by other parties.  NHK Spring included a brief suggestion that a parallel district court litigation may justify denial of institution.  Finally, Fintiv expanded on that suggestion, creating another set of non-statutory factors used to deny institution based on proceedings in other forums.

Decrease in Institution Driven by Discretionary Denials

Over the past few years, the percentage of all denials that are based on procedural denials has steadily increased.  Charts from Unified Patents illustrate this increase.

And, of these procedural denials, the vast majority are now derived from the § 314(a) discretionary denial decisions like General Plastic, NHK Spring, and Fintiv.

Discretionary denials were roughly constant prior to 2017; after General Plastic, they began to increase, and after Valve, NHK Spring, and Fintiv their usage accelerated rapidly, both in absolute number and as a percentage of all denials.  And as procedural denials increased, the positive benefits of IPR began to disappear.  

Impacts of Discretionary Denial on Patent System

The following charts, created by Patent Progress, show the fallout from the discretionary denial precedents.  The number of patent lawsuits, which had been falling, began to increase.

People started filing fewer IPRs.

The cost of NPE litigation increased in proportion to procedural denials.

The cost of IPR increased as well.  (While this graph shows the cost for electrical IPRs, other technologies experienced similar increases and IPRs on electrical technologies represent the majority of all IPRs.)

In other words, after the PTO made the discretionary denial opinions precedential, innovators were more likely to face patent lawsuits, less likely to be able to use the IPR process as a meaningful defense, and the total cost of defending themselves—both in court and at the PTAB—increased significantly.  

It’s also increased the costs for patent owners, who face a more expensive set of proceedings at the Patent Office and more expensive litigation overall.  While a discretionary denial might save them money at the Patent Office, it doesn’t provide a petitioner with any reason to back away from their invalidity theory—in fact, in cases like the recent Philip Morris IPRs, the petitioner might even be more likely to fight invalidity in court given the panel’s statement that their merits case was particularly strong.  And without a reason to back away, petitioners are more likely to fight in court, increasing overall costs for patent owners.

Cui Bono?

So who actually wins here?  Innovators—plaintiffs and defendants alike—are forced to spend more on less consistent proceedings, taking money away from their R&D efforts.The chief winners are patent lawyers and law firms, like Irell & Manella, Director Iancu’s former firm, which will have more trials to litigate, leading to more billable hours, and the patent trolls, like prolific filer Fortress Investment Group—represented by Irell & Manella in manycases—who receive higher value settlements when litigation costs increase.

Josh Landau

Patent Counsel, CCIA

Joshua Landau is the Patent Counsel at the Computer & Communications Industry Association (CCIA), where he represents and advises the association regarding patent issues.  Mr. Landau joined CCIA from WilmerHale in 2017, where he represented clients in patent litigation, counseling, and prosecution, including trials in both district courts and before the PTAB.

Prior to his time at WilmerHale, Mr. Landau was a Legal Fellow on Senator Al Franken’s Judiciary staff, focusing on privacy and technology issues.  Mr. Landau received his J.D. from Georgetown University Law Center and his B.S.E.E. from the University of Michigan.  Before law school, he spent several years as an automotive engineer, during which time he co-invented technology leading to U.S. Patent No. 6,934,140.

Follow @PatentJosh on Twitter.

More Posts

Another Litigation Funding Dispute

In what has become a recurring topic on Patent Progress, another dispute between a patent troll and a litigation funder has emerged. This time, it is between the Irish NPE, Arigna Technology; its law ...

USPTO Guidance on AI is a Good Start

AI is catalyzing a sea change across our economy, particularly as it relates to innovation. It is critical that our laws and institutions keep pace with this rapid transformation. Fortunately, patent ...

Patent Eligibility Limits are Vital to Innovation, Prosperity, and Public Health

A few weeks ago, several public interest organizations including the Public Interest Patent Law Institute (PIPLI), the American Civil Liberties Union (ACLU), Electronic Frontier Foundation (EFF), Gene...

Subscribe to Patent Progress

No spam. Unsubscribe anytime.